Biography
Dr. Prasad S. Adusumilli is the Deputy Chief of the Thoracic Service and Co-Director of the Mesothelioma Program at Memorial Sloan Kettering Cancer Center. He is an internationally recognized pioneer in CAR T-cell therapy for mesothelioma, leading clinical trials that target the mesothelin protein expressed on mesothelioma tumor cells. His laboratory and clinical work have positioned MSK at the forefront of cellular immunotherapy for thoracic cancers. Dr. Adusumilli performs pleurectomy with decortication and integrates novel immunotherapeutic approaches into surgical treatment plans for mesothelioma patients.
Education & Training
- Medical Degree — Kasturba Medical College, Manipal University (Medicine)
- Residency — University of Iowa Hospitals (General Surgery)
- Fellowship — Memorial Sloan Kettering Cancer Center (Thoracic Surgery)
Specialties & Procedures
Clinical Specialties
- Thoracic Surgery
- Surgical Oncology
- Immunotherapy
Surgical Procedures
Board Certifications
- American Board of Thoracic Surgery
Research Focus
CAR T-cell therapy for mesothelioma, mesothelin-targeted immunotherapy, and translational research bridging surgical oncology with cellular therapy.
Legal Resources for Mesothelioma Patients
Patients diagnosed with mesothelioma after asbestos exposure may be eligible for compensation through asbestos trust funds and legal claims. Over $30 billion remains available in trust funds nationwide.
Frequently Asked Questions
What is Dr. Adusumilli's CAR T-cell research for mesothelioma?
Dr. Adusumilli leads clinical trials at MSK using CAR T-cells engineered to target mesothelin, a protein found on mesothelioma cells. This approach trains the patient's own immune cells to recognize and attack the cancer, representing a promising new treatment avenue.
Does Dr. Adusumilli perform mesothelioma surgery?
Yes. Dr. Adusumilli performs pleurectomy with decortication (P/D) as part of a multimodal treatment plan that may include his pioneering immunotherapy protocols.